Tagged as: HIV prevention

Realistic ambitions for advocacy projects 30 Jan 2025

Learning from the experiences of United for Prevention programme can support designers, funders and civil society actors who are planning or involved ...

Find out more
How peer workers are spearheading harm reduction in Egypt 20 Jan 2025

In the third instalment of our blog series, we spotlight community members who are changing the face of harm reduction in Egypt. Through their stories...

Find out more
Emergency support as the lifeline for LGBTQ+ activists facing violence 26 Nov 2024

The rise of anti-rights movements means that some LGBTQ+ organisations are having to take emergency measures to stay safe. As the 16 Days of Activism ...

Find out more
From political activism to harm reduction in Nigeria: Aniedi Akpan’s journey 08 Nov 2024

In the second instalment of our blog series, we meet another community member who is changing the face of harm reduction. We get a unique insight into...

Find out more
Trump is a threat in fight against AIDS, but we must hold the line 08 Nov 2024

Donald Trump’s return to the White House for a second term inflicts a hammer blow to LGBTQ+ rights and access to abortion within the U.S., as well a...

Find out more
Why the US elections matter for ending AIDS 05 Nov 2024

Frontline AIDS does not endorse political parties nor support candidates, but in the wake of the US election result we cannot deny the importance of i...

Find out more
Angela McBride: Redefining harm reduction in South Africa 01 Nov 2024

In the first instalment of our blog series, we profile Angela McBride, a pioneering activist transforming harm reduction in South Africa. This is her ...

Find out more
Funding boost to challenge LGBTQ+ rights violations 11 Oct 2024

Frontline AIDS’ Rapid Response Fund has received a $300,000 USD funding commitment from the Elton John AIDS Foundation (the Foundation) to tackle an...

Find out more
Lenacapavir: A potential game-changer in HIV prevention – what stands in the way? 23 Sep 2024

This year, researchers unveiled major interim results from two Phase 3 trials of injectable lenacapavir (LEN-LA). This new long-acting injectable, adm...

Find out more